Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  

High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study

Xia et al., Aging, doi:10.18632/aging.203503
Xia et al., High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study, Aging, doi:10.18632/aging.203503
Sep 2021   Source   PDF  
  All Studies   Meta
Retrospective 113 severe and critical patients in China with cardiac injury, 51 treated with high dose vitamin C, showing treatment associated with improvement of myocardial injury.
Xia et al., 7 Sep 2021, China, peer-reviewed, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study
Guozhi Xia, Bowen Qin, Chaoran Ma, Yaowu Zhu, Qiangsun Zheng
Background: Cardiac injury is common and associated with poor clinical outcomes in COVID-19. Data are lacking whether high-dose intravenous vitamin C (HIVC) could help to ameliorate myocardial injury in the pandemic. Methods: The retrospective cohort study included consecutive severe and critically ill COVID-19 patients with cardiac injury receiving symptomatic supportive treatments alone or together with HIVC. Troponin I and inflammatory markers were collected at admission and day 21 during hospitalization from the electronic medical records. Results: The patients (n = 113) were categorized into the ameliorated cardiac injury (ACI) group (n = 70) and the non-ameliorated cardiac injury (NACI) group (n = 43). Overall, fifty-one (45.1%) patients were administered with HIVC, the percentages of patients with HIVC were higher in the ACI group than those in the NACI group. Logistic regression analysis revealed that HIVC was independently associated with the improvement of myocardial injury. Further analysis showed that inflammatory markers levels significantly decreased at day 21 during hospitalization in patients with HIVC therapy compared to those administered with symptomatic supportive treatments alone. Meanwhile, similar results were also observed regarding changes in inflammatory markers levels from baseline to day 21 during hospitalization in the patients treated with HIVC. Conclusions: HIVC can ameliorate cardiac injury through alleviating hyperinflammation in severe and critically ill patients with COVID-19.
AUTHOR CONTRIBUTIONS Xia G conceived and designed of the study. Xia G and Zhu Y collected the clinical data and laboratory values. Xia G and Ma C drafted the article. Xia G and Qin B conducted the statistical analysis and interpreted the data. Zheng Q provided valuable guidance in every stage of the writing of this thesis. All authors read and approved the final manuscript. CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.
Basili, Tanzilli, Mangieri, Raparelli, Santo et al., Intravenous ascorbic acid infusion improves myocardial perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers, JACC Cardiovasc Interv, doi:10.1016/j.jcin.2009.10.025
Bavishi, Bonow, Trivedi, Abbott, Messerli et al., Special Article -Acute myocardial injury in patients hospitalized with COVID-19 infection: A review, Prog Cardiovasc Dis, doi:10.1016/j.pcad.2020.05.013
Carr, Rowe, The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19, Nutrients, doi:10.3390/nu12113286
Fowler Aa 3rd, Syed, Knowlson, Sculthorpe, Farthing et al., Unit Nursing. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis, J Transl Med, doi:10.1186/1479-5876-12-32
Fowler Aa 3rd, Truwit, Hite, Morris, Dewilde et al., Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial, JAMA, doi:10.1001/jama.2019.11825
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Kashiouris, Heureux, Cable, Fisher, Leichtle et al., The Emerging Role of Vitamin C as a Treatment for Sepsis, Nutrients, doi:10.3390/nu12020292
Lin, Li, Interpretation of "Guidelines for the Diagnosis and Treatment of Novel Coronavirus
Madjid, Vela, Khalili-Tabrizi, Casscells, Litovsky, Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes, Tex Heart Inst J
Min, Cheon, Ha, Sohn, Kim et al., Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity, Sci Rep, doi:10.1038/srep25359
Qin, Zhou, Hu, Zhang, Yang et al., Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China, Clin Infect Dis, doi:10.1093/cid/ciaa248
Shi, Qin, Shen, Cai, Liu et al., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiol, doi:10.1001/jamacardio.2020.0950
Vf, Musher, Shachkina, Chirinos, Acute pneumonia and the cardiovascular system, Lancet, doi:10.1016/S0140-6736(12)61266-5
Wang, Hu, Liu, Shi, Cheng et al., The effect of intravenous vitamin C infusion on periprocedural myocardial injury for patients undergoing elective percutaneous coronary intervention, Can J Cardiol, doi:10.1016/j.cjca.2013.08.018
Xia, Fan, He, Zhu, Zheng, High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019, Nutrition, doi:10.1016/j.nut.2021.111405
Xia, Ma, He, Wang, Zhu et al., Hyper-Inflammatory Response Involves in Cardiac Injury Among Patients With Coronavirus Disease 2019, Am J Med Sci, doi:10.1016/j.amjms.2021.02.007
Yang, Tang, Aberrant coagulation causes a hyperinflammatory response in severe influenza pneumonia, Cell Mol Immunol, doi:10.1038/cmi.2016.1
Zhang, Rao, Li, Zhu, Liu et al., Pilot trial of high-dose vitamin C in critically ill COVID-19 patients, Ann Intensive Care, doi:10.1186/s13613-020-00792-3
Zheng, Ma, Zhang, Xie, COVID-19 and the cardiovascular system, Nat Rev Cardiol, doi:10.1038/s41569-020-0360-5
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop